PathAI said April 17 that it raised $60 million in Series B funding led by General Atlantic. General Catalyst invested in the round and other existing investors. PathAI, of Boston, provides artificial intelligence-powered technology for pathology.
PathAI Secures $60M in Series B Funding Led by General Atlantic and Existing Investor General Catalyst
Computational Pathology Leader Plans to Accelerate Industry Impact
Boston, Mass. – April 17, 2019 – PathAI, a global provider of artificial intelligence-powered technology for pathology, announced today that it has raised $60 million in Series B funding. The round was led by new investorGeneral Atlantic, a leading global growth equity firm, with strong participation from General Catalyst and other existing investors. The new capital will fuel PathAI’s continued expansion as the company seeks to advance the medical discipline of pathology. General Atlantic Managing Director Dr. Michelle Dipp will be joining PathAI’s board of directors as the company advances its mission of offering faster, safer, and more powerful solutions for the diagnosis and sub-typing of diseases like cancer.
PathAI plans to use this new capital to enhance offerings to existing partners, drive continuous improvement of its flagship pathology research platform, meet market demands, and fuel research and development into new tools and medical devices. Its growing partnerships with leading global pharmaceutical companies seek to accelerate drug development in life-saving therapeutics, and its partnerships with leading diagnostic laboratories aim to support pathologists in bringing faster, more accurate, and more predictive diagnostics to patients.